FDA staff question Pfizer arthritis drug benefits

WASHINGTON (Reuters) – U.S. drug reviewers on Monday questioned whether the benefits of Pfizer Inc’s experimental treatment for rheumatoid arthritis outweighed its risks of cancerous cells and infections.